Exome Sequencing Data
Buy and sell exome sequencing data data. Protein-coding regions where most disease mutations hide — cheaper than whole genome but equally valuable for rare disease AI.
No listings currently in the marketplace for Exome Sequencing Data.
Find Me This Data →Overview
What Is Exome Sequencing Data?
Exome sequencing targets the protein-coding regions of the genome where the vast majority of disease-causing variants reside, making it a cost-effective alternative to whole-genome sequencing. The exome sequencing market has experienced significant growth driven by dramatic cost reductions—sequencing costs have fallen to the low hundreds of dollars per exome, democratizing access to genetic research and clinical diagnostics. This technology is now widely deployed across research institutions, clinical diagnostic laboratories, and pharmaceutical companies for rare disease diagnosis, complex disease research, and drug discovery applications.
Market Data
USD 308.5 million
Global Exome Sequencing Market Size (2022)
Source: Data Insights Market
4.7%
Exome Sequencing CAGR
Source: Data Insights Market
130.03 to 818.81 USD Million at 20% CAGR
UK Market Projected Growth (2025-2035)
Source: Market Research Future
USD 785.15 million, growing to USD 4,280.91 million by 2034
Europe Market Valuation (2025)
Source: Market Data Forecast
Who Uses This Data
What AI models do with it.do with it.
Rare Disease Diagnosis
Clinical diagnostic laboratories and research institutions use exome sequencing to identify genetic causes of undiagnosed rare conditions, enabling powerful tools for genetic diagnosis and disease discovery.
Complex Disease Research
Beyond Mendelian disease, exome sequencing is increasingly leveraged for studying complex diseases including cardiovascular disease, diabetes, and neurological disorders to identify rare and low-frequency variants.
Pharmaceutical Drug Discovery
Pharmaceutical companies use exome sequencing data to accelerate drug discovery processes and understand genetic variants relevant to therapeutic targets.
Personalized Medicine Development
Expanding applications in personalized medicine leverage exome sequencing to tailor treatments based on individual genetic profiles.
What Can You Earn?
What it's worth.worth.
Research-Grade Exome
Under $500 per sample
Costs have fallen significantly due to advances in probe design and library preparation, democratizing access to sequencing studies.
Clinical Integration Services
Varies
Downstream analysis, bioinformatics, variant annotation, and clinical integration remain substantial cost components beyond raw sequencing.
Data Licensing & Analysis
Varies
Market pricing for exome data sets and analytical services varies based on sample size, quality metrics, and standardization requirements.
What Buyers Expect
What makes it valuable.valuable.
Coverage Depth & Variant Detection
Buyers require deeper coverage and improved probe designs to detect challenging variants and achieve comprehensive genetic insights from protein-coding regions.
Data Quality Control & Standardization
Increased focus on quality control metrics and standardization protocols for exome sequencing data ensures consistency and clinical applicability across studies.
Bioinformatics & AI-Powered Analysis
Advancements in bioinformatics and AI-powered analytical tools are crucial for efficient interpretation of genetic data and identifying disease-causing variants.
Privacy, Regulatory & Ethical Compliance
Handling of sensitive genetic data requires adherence to evolving regulatory frameworks, data privacy standards, consent protocols, and ethical guidelines for clinical applications.
Companies Active Here
Who's buying.buying.
Leading player in exome sequencing platforms and kits with 28.1% market share, dominant in research and clinical diagnostics.
Major provider of sequencing instruments and exome sequencing solutions with 16.6% market share across research and diagnostic applications.
Significant player in clinical diagnostic sequencing and personalized medicine with 15.1% market share, focusing on integrated genomic solutions.
Developer of probe designs and library preparation kits with 14.4% market share, advancing cost-effective sequencing workflows.
Major provider of genomic testing services and sequencing infrastructure with 10.4% market share in exome sequencing markets.
FAQ
Common questions.questions.
Why is exome sequencing cheaper than whole genome sequencing?
Exome sequencing targets only the protein-coding regions of the genome, which represent about 1-2% of the total DNA but contain the vast majority of disease-causing variants. This focused approach requires less sequencing depth and data processing, dramatically reducing costs while maintaining clinical and research value. Costs now often fall below $500 per exome for research purposes.
What are the main challenges in the exome sequencing data market?
Key challenges include complex data interpretation, especially for variants of unknown significance; high costs of downstream bioinformatics analysis and clinical integration; ethical and privacy concerns with sensitive genetic data; evolving regulatory requirements for clinical diagnostics; and the need for standardized protocols across research and clinical settings.
Which regions show the strongest growth in exome sequencing markets?
The UK whole exome sequencing market is projected to grow at 20% CAGR from 2025 to 2035, reaching 818.81 USD million by 2035. Europe's market is valued at USD 785.15 million in 2025 and is expected to grow to USD 4,280.91 million by 2034 at a 20.74% CAGR. Advanced biobanking infrastructure, progressive reimbursement policies, and clinical integration are driving growth in these regions.
What future developments are expected in the exome sequencing market?
Anticipated developments include emergence of more cost-effective and streamlined exome sequencing workflows for routine clinical use by late 2025; increased focus on quality control metrics and standardization; continuous innovation in probe design and sequencing chemistry to achieve deeper coverage and detect challenging variants; and broader clinical integration alongside AI-powered analytical tools for more efficient data interpretation.
Sell yourexome sequencingdata.
If your company generates exome sequencing data, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation